1. Home
  2. THS vs NVCR Comparison

THS vs NVCR Comparison

Compare THS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THS
  • NVCR
  • Stock Information
  • Founded
  • THS 2021
  • NVCR 2000
  • Country
  • THS United States
  • NVCR Jersey
  • Employees
  • THS N/A
  • NVCR 1453
  • Industry
  • THS Packaged Foods
  • NVCR Medical/Dental Instruments
  • Sector
  • THS Consumer Staples
  • NVCR Health Care
  • Exchange
  • THS Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • THS N/A
  • NVCR 3.2B
  • IPO Year
  • THS N/A
  • NVCR 2015
  • Fundamental
  • Price
  • THS $34.91
  • NVCR $30.09
  • Analyst Decision
  • THS Hold
  • NVCR Buy
  • Analyst Count
  • THS 5
  • NVCR 5
  • Target Price
  • THS $34.20
  • NVCR $33.40
  • AVG Volume (30 Days)
  • THS 599.0K
  • NVCR 1.3M
  • Earning Date
  • THS 02-14-2025
  • NVCR 02-20-2025
  • Dividend Yield
  • THS N/A
  • NVCR N/A
  • EPS Growth
  • THS N/A
  • NVCR N/A
  • EPS
  • THS N/A
  • NVCR N/A
  • Revenue
  • THS $3,359,100,000.00
  • NVCR $577,738,000.00
  • Revenue This Year
  • THS N/A
  • NVCR $19.13
  • Revenue Next Year
  • THS $1.26
  • NVCR $5.38
  • P/E Ratio
  • THS N/A
  • NVCR N/A
  • Revenue Growth
  • THS N/A
  • NVCR 14.63
  • 52 Week Low
  • THS $28.04
  • NVCR $11.70
  • 52 Week High
  • THS $43.84
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • THS 55.39
  • NVCR 60.15
  • Support Level
  • THS $34.08
  • NVCR $29.62
  • Resistance Level
  • THS $35.87
  • NVCR $30.87
  • Average True Range (ATR)
  • THS 0.91
  • NVCR 1.77
  • MACD
  • THS 0.27
  • NVCR -0.56
  • Stochastic Oscillator
  • THS 84.96
  • NVCR 23.28

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: